Provided by Tiger Trade Technology Pte. Ltd.

Adicet Bio, Inc.

7.04
-0.4300-5.76%
Post-market: 7.140.1000+1.42%18:05 EDT
Volume:86.40K
Turnover:619.75K
Market Cap:67.43M
PE:-0.35
High:7.44
Open:7.41
Low:6.97
Close:7.47
52wk High:17.44
52wk Low:6.41
Shares:9.58M
Float Shares:8.25M
Volume Ratio:0.74
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.1770
EPS(LYR):-21.3273
ROE:-71.73%
ROA:-39.13%
PB:0.62
PE(LYR):-0.33

Loading ...

Canaccord Genuity Remains a Buy on Adicet Bio (ACET)

TIPRANKS
·
Oct 17, 2025

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Adi-001 in Treatment-Refractory Rheumatoid Arthritis (Ra)

THOMSON REUTERS
·
Oct 16, 2025

Adicet Bio Inc - Preliminary Data From Phase 1 Trial Expected in 2H/2026

THOMSON REUTERS
·
Oct 16, 2025

Adicet Bio Is Maintained at Buy by Guggenheim

Dow Jones
·
Oct 08, 2025

Guggenheim Sticks to Their Buy Rating for Adicet Bio (ACET)

TIPRANKS
·
Oct 08, 2025

Adicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement

Reuters
·
Oct 08, 2025

Adicet Bio Announces $80 Million Registered Direct Offering of Common Stock and Pre-Funded Warrants

Reuters
·
Oct 07, 2025

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Announces Positive Phase 1 Results for ADI-001 in Lupus Nephritis and SLE, Plans Pivotal Phase 2 Trial in 2026

Reuters
·
Oct 07, 2025

Adicet Bio Inc - Adi-001 Well Tolerated With No Icans Observed

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Announces Positive Preliminary Data From Adi-001 Phase 1 Study in Patients With Lupus Nephritis (Ln) and Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Inc - Plans FDA Meeting in 1Q/2026 for Phase 2 Trial

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Inc - as of Aug 31, All Patients Show Reductions in Sledai-2K Score

THOMSON REUTERS
·
Oct 07, 2025

BRIEF-Adicet Bio Reports Inducement Grant Under Nasdaq Listing Rule

Reuters
·
Oct 01, 2025

Adicet Bio Grants Inducement Stock Options to New Hire Under 2022 Inducement Plan

Reuters
·
Oct 01, 2025

Adicet Bio Price Target Maintained With a $7.00/Share by Guggenheim

Dow Jones
·
Sep 19, 2025